Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310632 · ClinicalTrials.gov registry record · Phase 1
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Golden Biotechnology Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT03310632 is a Phase 1 study that has completed, run by Golden Biotechnology Corporation. The registered enrollment target is 55 participants.
The verdict
NCT03310632, a Phase 1 study, has completed, sponsored by Golden Biotechnology Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
Antroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg TID and 300 mg TID, clinical treatment duration of 4 weeks, to determine the MTD or MFD (based on PK and capsules strength) of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine. The extended Phase II will focus on the efficacy of antroquinonol with SOC. Safety and pharmacokinetic profiles will be studied in the proposed clinical trial.
Interventions
- DRUG Antroquinonol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2024-01-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03310632
The ClinicalTrials.gov registry entry for NCT03310632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Golden Biotechnology Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antroquinonol is the first listed.
NCT03310632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03310632 about?
NCT03310632 is a clinical study titled "Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer". Antroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. The first part of st...
What is the current status of trial NCT03310632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2017-12-01. Estimated completion is 2024-01-02.
What interventions are being tested in trial NCT03310632?
The interventions under investigation include: Antroquinonol (DRUG).
Who is sponsoring clinical trial NCT03310632?
This trial is sponsored by Golden Biotechnology Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.